X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUN PHARMA AUROBINDO PHARMA/
SUN PHARMA
 
P/E (TTM) x 13.9 32.5 42.8% View Chart
P/BV x 2.8 2.7 103.6% View Chart
Dividend Yield % 0.4 0.5 95.7%  

Financials

 AUROBINDO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
SUN PHARMA
Mar-18
AUROBINDO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs809701 115.5%   
Low Rs504433 116.3%   
Sales per share (Unadj.) Rs281.1110.4 254.6%  
Earnings per share (Unadj.) Rs41.411.0 376.7%  
Cash flow per share (Unadj.) Rs50.917.2 295.3%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.4 107.9%  
Book value per share (Unadj.) Rs199.4158.8 125.5%  
Shares outstanding (eoy) m585.882,399.26 24.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.35.1 45.5%   
Avg P/E ratio x15.951.6 30.7%  
P/CF ratio (eoy) x12.932.9 39.2%  
Price / Book Value ratio x3.33.6 92.3%  
Dividend payout %6.018.2 33.2%   
Avg Mkt Cap Rs m384,6301,360,021 28.3%   
No. of employees `00017.317.8 97.4%   
Total wages/salary Rs m21,30853,671 39.7%   
Avg. sales/employee Rs Th9,500.714,890.9 63.8%   
Avg. wages/employee Rs Th1,229.43,017.1 40.7%   
Avg. net profit/employee Rs Th1,397.91,480.6 94.4%   
INCOME DATA
Net Sales Rs m164,666264,895 62.2%  
Other income Rs m1,0208,388 12.2%   
Total revenues Rs m165,686273,282 60.6%   
Gross profit Rs m37,71856,081 67.3%  
Depreciation Rs m5,58014,998 37.2%   
Interest Rs m7775,176 15.0%   
Profit before tax Rs m32,38044,295 73.1%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m8,1838,452 96.8%   
Profit after tax Rs m24,22926,338 92.0%  
Gross profit margin %22.921.2 108.2%  
Effective tax rate %25.319.1 132.4%   
Net profit margin %14.79.9 148.0%  
BALANCE SHEET DATA
Current assets Rs m121,878316,359 38.5%   
Current liabilities Rs m86,806198,643 43.7%   
Net working cap to sales %21.344.4 47.9%  
Current ratio x1.41.6 88.2%  
Inventory Days Days13095 137.0%  
Debtors Days Days68108 63.5%  
Net fixed assets Rs m81,037213,178 38.0%   
Share capital Rs m5862,399 24.4%   
"Free" reserves Rs m116,218378,606 30.7%   
Net worth Rs m116,804381,006 30.7%   
Long term debt Rs m4,51217,721 25.5%   
Total assets Rs m211,052643,028 32.8%  
Interest coverage x42.79.6 446.3%   
Debt to equity ratio x00 83.1%  
Sales to assets ratio x0.80.4 189.4%   
Return on assets %11.84.9 241.8%  
Return on equity %20.76.9 300.1%  
Return on capital %27.410.0 272.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72740,816 197.8%   
Fx outflow Rs m34,70030,143 115.1%   
Net fx Rs m46,02710,673 431.2%   
CASH FLOW
From Operations Rs m19,54839,072 50.0%  
From Investments Rs m-19,570-33,708 58.1%  
From Financial Activity Rs m8,642-15,393 -56.1%  
Net Cashflow Rs m8,922-7,359 -121.2%  

Share Holding

Indian Promoters % 54.1 63.7 84.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.1 155.0%  
FIIs % 27.7 23.0 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.3 122.9%  
Shareholders   69,601 133,026 52.3%  
Pledged promoter(s) holding % 8.6 0.5 1,615.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex below 38,000-Mark, HUL, L&T Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets extended their decline for the 4th day as markets witnessed selling pressure during closing hours.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 23, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ABBOTT INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS